Potential of Favipiravir and Minocycline Combination Therapy for COVID-19
Re:GEN Open · 2022
DOI: 10.1089/regen.2021.0037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Re:GEN Open, 2022. Verfasst von Kazuhiro Itoh und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Since the outbreak and spread of COVID-19 in Japan, we have been investigating and anticipating the possibility of anti-inflammatory effects in combination therapy with antibacterial and antiviral agents. Minocycline is an antibacterial agent that has been validated for its anti-inflammatory effects and has a broad antibacterial spectrum. In the present study, we hypothesized the possibility of combination therapy with minocycline and favipiravir for COVID-19. Here, we validated our hypothesis based on the results of preliminary basic experiments and clinical trials. Large-scale clinical trials of minocycline and favipiravir combination therapy are warranted.
Zitieren
APA
Itoh, K., Tsutani, H., & Iwasaki, H. (2022). Potential of Favipiravir and Minocycline Combination Therapy for COVID-19. Re:GEN Open. https://doi.org/10.1089/regen.2021.0037
Vancouver
Itoh K, Tsutani H, Iwasaki H. Potential of Favipiravir and Minocycline Combination Therapy for COVID-19. Re:GEN Open. 2022. doi:10.1089/regen.2021.0037
BibTeX
@article{Itoh2022,
author = {Itoh, Kazuhiro and Tsutani, Hiroshi and Iwasaki, Hiromichi},
title = {Potential of Favipiravir and Minocycline Combination Therapy for COVID-19},
journal = {Re:GEN Open},
year = {2022},
doi = {10.1089/regen.2021.0037}
}
EUVIMED